Weight management
Weight loss is the effect semaglutide is now most widely known for, particularly in people living with obesity or overweight.
Explore the research →GLP-1 & METABOLIC HEALTH
Semaglutide
A widely used, extensively studied medicine for type 2 diabetes and weight management, semaglutide affects appetite, blood sugar and body weight.
Weight managementGlucose controlAppetite
Extensive human evidenceLarge randomized programmes and real-world use provide a mature evidence base for approved indications, alongside well-characterised gastrointestinal and other safety considerations.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why is Semaglutide so widely used and studied?
Semaglutide is best known for reducing appetite, helping people feel fuller and supporting blood-sugar control — effects that can lead to meaningful weight loss. That combination has made it one of the best-known treatments in modern weight management and explains why interest extends well beyond diabetes.
Blood sugar control
Semaglutide was established as a diabetes treatment before its use for weight management became so prominent.
Explore the research →Appetite & feeling full
Many people notice that they feel fuller sooner and think about food less, helping to explain why semaglutide can have such a strong effect on weight.
Explore the research →Heart health
Research has also asked whether the benefits of semaglutide extend beyond weight and blood sugar to important cardiovascular outcomes.
Explore the research →THE SCIENCE BIT
One receptor. A powerful appetite signal.
Semaglutide activates the GLP-1 receptor, a message receiver used by a hormone released after eating. Its signals influence appetite, insulin release and the speed at which the stomach empties.
Its long-lasting design allows once-weekly formulations. The receptor story explains how it works; human trials establish the outcomes of specific medicines and doses.
See the studies & trials →- GLP-1R
- The main receptor target
- Insulin
- Glucose-dependent release
- Appetite
- Brain and gut signalling
How this connects to the research
Established pharmacology with extensive human trial evidence.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where Semaglutide connects with the body
These are the tissues and biological systems behind the interest in Semaglutide.
- Brain
- Appetite and food intake.
- Pancreas
- Insulin and glucagon responses.
- Stomach
- Gastric emptying.
The research behind the interest
Weight management
Weight loss is the effect semaglutide is now most widely known for, particularly in people living with obesity or overweight.
Large human trials consistently show meaningful average weight loss when semaglutide is used alongside lifestyle support.
Strong human evidenceExplore the studies →Blood sugar control
Semaglutide was established as a diabetes treatment before its use for weight management became so prominent.
Multiple trials show significant improvements in HbA1c and other measures of blood-sugar control in people with type 2 diabetes.
Strong human evidenceExplore the studies →Appetite & feeling full
Many people notice that they feel fuller sooner and think about food less, helping to explain why semaglutide can have such a strong effect on weight.
Human studies support reductions in appetite and food intake, alongside effects on how quickly food leaves the stomach.
Strong human & mechanistic evidenceExplore the studies →Heart health
Research has also asked whether the benefits of semaglutide extend beyond weight and blood sugar to important cardiovascular outcomes.
Large outcome trials have shown cardiovascular benefit in selected groups at higher risk of heart and circulatory disease.
Strong outcome evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableOnce-Weekly Semaglutide in Adults with Overweight or Obesity ↗
1,961 adults with overweight or obesity without diabetes
SubcutaneousOnce weekly68 weeks
Semaglutide 2.4 mg plus lifestyle intervention produced substantially greater average weight loss than placebo.
Gastrointestinal adverse effects were among the most common treatment-related events.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceExtensive
5/5 evidence depth
✓
Clinical efficacyExtensive
5/5 evidence depth
This score reflects completed human outcome evidence. A registered or recruiting trial does not count until results are reported.
◇
Safety evidenceExtensive
5/5 evidence depth
⌁
Preclinical evidenceStrong
4/5 evidence depth
HOW TO READ THESE SCORESStrong preclinical evidence · extensive human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
Semaglutide research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01Weight management
RESEARCH AREA 02Glucose control
RESEARCH AREA 03Appetite
RESEARCH AREA 04Cardiometabolic health
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Semaglutide
People most often discuss semaglutide around appetite, gradual weight change, dose-escalation tolerability and preserving strength while losing weight. These experiences are useful for understanding practical questions, but individual results can differ substantially from trial averages.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
An eating pattern that feels easier to maintain
People value quieter hunger, less grazing and feeling satisfied sooner. The everyday goal is being able to follow a workable eating pattern without constantly pushing against appetite.
- What makes a report informative
- Hunger, meal satisfaction and unplanned eating across the week.
- What can muddy the picture
- Not wanting food because of nausea is different from comfortable appetite control.
Weight loss that translates into daily life
Progress can mean a smaller waist, easier walking or more comfortable clothing. Plateaus attract attention because visible improvement and the scale do not always move together.
- What makes a report informative
- Longer-term weight and waist trends, movement and clothing fit.
- What can muddy the picture
- Short-term fluid changes and constipation can obscure the underlying trend.
Keeping strength and wellbeing while weight falls
People also want to stay capable at work and in training, with manageable digestion and enough nutrition. Success is broader than the fastest possible loss on the scales.
- What makes a report informative
- Strength, energy, food tolerance and bowel comfort.
- What can muddy the picture
- Training, protein intake and total food intake strongly influence these experiences.
FROM PUBLIC DISCUSSIONS
Experiences worth looking at
Selected first-hand accounts illustrate the goals and the variation in experience. They are examples, not a representative sample or proof of an effect.
What quieter food noise means in daily life
People describe less mental attention to snacks and meals, illustrating why the experience can matter beyond a weight measurement.
Read the discussionAn account where food noise persisted
This report separates ongoing cravings from nausea and weight change, showing why those experiences should not be treated as interchangeable.
Read the discussionPUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Reduced appetite and earlier fullness
Human findings & limits
Randomized trials consistently show lower energy intake and clinically meaningful average weight loss, supporting a real appetite-related effect.
Laboratory & animal context
GLP-1 receptor signalling has established roles in satiety, gastric emptying and glucose-dependent insulin pathways.
What this means: A well-supported human effect, although its strength and day-to-day experience vary between individuals.
Steady weight loss followed by plateaus
Human findings & limits
Large obesity trials show substantial average weight reduction over many months, with wide individual variation and a slowing of loss over time.
Laboratory & animal context
Energy-intake and metabolic pathways provide a biological rationale, but they do not predict an individual's final response.
What this means: Weight reduction is strongly supported; the amount, pace and timing of a plateau cannot be predicted from community reports.
Nausea or bowel changes during dose escalation
Human findings & limits
Gastrointestinal adverse effects such as nausea, diarrhoea, vomiting and constipation are well documented in clinical trials and authorised product information.
Laboratory & animal context
Effects on gastrointestinal motility and central appetite signalling offer a plausible mechanism for some of these experiences.
What this means: A recognised tolerability issue rather than proof that the medicine is working; persistent or severe symptoms need clinical review.
Maintaining muscle and strength while weight falls
Human findings & limits
Body-composition studies show that weight loss can include lean mass as well as fat mass; the clinical goal is not simply the lowest scale weight.
Laboratory & animal context
There is no basis for treating semaglutide itself as a muscle-preserving compound.
What this means: An important practical concern. Resistance exercise, nutrition and medical context should be considered separately from the drug's weight-loss effect.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
Approved semaglutide dosing depends on the licensed product and indication; research protocols should not be treated as personalised dosing advice.
PUBLISHED HUMAN RESEARCH
View source ↗STEP 1 obesity trial ↗
Adults with overweight or obesity without diabetes
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Adults with overweight or obesity without diabetes. Route: Injection under the skin (SubQ). The study lasted 68 weeks. The figures below describe the research design, not a personal schedule.
| First amount studied | 0.25 mg weekly |
|---|---|
| Later or target amount | 2.4 mg weekly target |
| How often? | once a week |
| How was it given? | Injection under the skin (SubQ) |
| How long? | 68 weeks |
See the exact study wording +
Start / initial: 0.25 mg weekly
End / target: 2.4 mg weekly target
Frequency: Once weekly
Route: Subcutaneous
Study duration: 68 weeks
Source: NEJM 2021 · NCT03548935 ↗
Trial escalation protocol; licensed prescribing information should govern clinical use.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
UK licensed escalation example
UK product informationThis mirrors the staged weekly escalation in current UK Wegovy product information to the 2.4 mg maintenance dose. It is shown as a licensed reference schedule, not a personalised instruction.
Form and route: Weekly subcutaneous injection
| Calendar stage | Amount each time |
|---|---|
| Weeks 1–4 | 0.25 mg |
| Weeks 5–8 | 0.5 mg |
| Weeks 9–12 | 1 mg |
| Weeks 13–16 | 1.7 mg |
| Then onwards | 2.4 mg |
Frequency: Once weekly · 1 entry per scheduled day.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with Semaglutide
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDSemaglutide
→
OFTEN EXPLORED WITHCagrilintide / CagriSema research
Semaglutide + Cagrilintide
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
Safety context
SAFETY & UNCERTAINTY
Established tolerability data, with important warnings
What the current evidence saysSemaglutide has a large human safety database. Gastrointestinal effects are common, particularly during escalation. Authorised product information also addresses less common but important risks and precautions, including pancreatitis, gallbladder disease and dehydration-related kidney problems.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Why this matters
Approved semaglutide products have defined formulations and prescribing information. Unapproved, counterfeit or incorrectly compounded products add separate risks involving identity, concentration, dosing and quality.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
7 sourcesSources used on this profile
Peer-reviewed human trialOnce-Weekly Semaglutide in Adults with Overweight or ObesityNEJM ↗Bibliographic recordOnce-Weekly Semaglutide in Adults with Overweight or ObesityPubMed ↗Original publicationOnce-Weekly Semaglutide in Adults with Overweight or ObesityJournal / DOI ↗Trial registryOnce-Weekly Semaglutide in Adults with Overweight or ObesityClinicalTrials.gov ↗Official regulatory sourceSafety and uncertaintyWegovy · EMA medicine overview ↗Official safety sourceSafety and uncertaintyFDA · unapproved GLP-1 concerns ↗Professional sourceResearch combinationsREDEFINE 1 · PubMed ↗
CURRENT STATUS
How to interpret its position today
Authorised for defined indications
Wegovy is authorised for weight management in specified populations alongside diet and physical activity. Other semaglutide brands and formulations have their own indications and dosing information.
EMA · Wegovy overview ↗Cagrilintide combination remains a separate evidence question
Coadministered cagrilintide and semaglutide has Phase 3 human evidence. Those findings belong to the studied combination and should not be transferred to informal stacking or unverified mixed products.
REDEFINE 1 · PubMed ↗Unapproved products carry additional risk
FDA has highlighted dosing, ingredient and quality concerns with unapproved GLP-1 products used for weight loss.
FDA safety information ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.